Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings estimates for Karyopharm Therapeutics in a research note issued on Monday, November 3rd. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($11.22) for the year, down from their prior forecast of ($10.50). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ Q4 2025 earnings at ($1.66) EPS and FY2026 earnings at ($2.18) EPS.

Several other equities research analysts also recently issued reports on KPTI. Weiss Ratings reissued a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday. HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Monday, October 13th. Royal Bank Of Canada dropped their price target on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday. Piper Sandler restated an “overweight” rating and issued a $12.00 price target (down from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday, October 9th. Finally, Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Karyopharm Therapeutics Price Performance

NASDAQ:KPTI opened at $5.22 on Thursday. The business’s 50-day simple moving average is $6.22 and its 200-day simple moving average is $5.40. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $14.24. The stock has a market capitalization of $45.26 million, a PE ratio of -0.36 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The company had revenue of $44.04 million for the quarter, compared to analyst estimates of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KPTI. Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $163,000. Bank of America Corp DE boosted its holdings in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the last quarter. Baird Financial Group Inc. bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at $45,000. Silverback Asset Management LLC increased its holdings in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after buying an additional 20,000 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Karyopharm Therapeutics during the second quarter worth $56,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).